• InterView
• ‘Even a 0.2 vision is a miracle to some’
• by Eo, Yun-Ho May 15, 2023 05:41am

• InterView
• Samsung Bio, investing in Swiss ADC bio company
• by Hwang, Jin-joon Apr 13, 2023 05:43am

• InterView
• CDK4/6 latecomer Kisqali exudes confidence in its effect
• by Jung, Sae-Im Apr 11, 2023 06:11am

• InterView
• The rebate effect is not just employee deviation
• by Kim JiEun Mar 22, 2023 05:47am

• InterView
• ‘Reimbursing Revlimid as maintenance therapy beneficial’
• by Eo, Yun-Ho Mar 16, 2023 05:45am

• InterView
• SGLT-2 I is a great help in the treatment of heart failure
• by Kim, Jin-Gu Feb 6, 2023 05:51am

• InterView
• Takeda will lead industry with focus on Oncology
• by Eo, Yun-Ho Feb 2, 2023 05:47am

• InterView
• “Novartis will lead the provision of innovative medicines”
• by Eo, Yun-Ho Jan 25, 2023 06:08am

• InterView
• Avodart, Real World Data
• by Dec 28, 2022 05:48am

• InterView
• IL-23 Continued research on inflammatory pathways
• by Dec 23, 2022 06:05am